23 Paul Tudor Jones II Ionis Pharmaceuticals Trades
The first Ionis Pharmaceuticals trade was made in Q2 2016. Since then Paul Tudor Jones II bought shares thirteen more times and sold shares on eleven occasions. The investor sold all their shares in Q4 2024 and doesn't own any shares in Ionis Pharmaceuticals anymore.
News about Ionis Pharmaceuticals Inc and Paul Tudor Jones II
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Pha...
Biogen updates Phase 1 data for Ionis-partnered Alzheimer’s drug
Biogen (BIIB) said its Ionis (IONS) partnered Alzheimer''s candidate, BIIB080, showed promising clinical trends in Phase 1b trial. Read more here.
Biogen ALS drug tofersen earns mixed voting by FDA advisory panel
An FDA advisory panel gave mixed signals Wednesday in two votes regarding Biogen (BIIB) and Ionis Pharmaceuticals (IONS) amyotrophic lateral sclerosis (ALS) ...